 Valentina Todorova
Concepts (193)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Doxorubicin | 10 | 2024 | 236 | 4.610 |
Why?
| | Breast Neoplasms | 12 | 2024 | 1201 | 2.320 |
Why?
| | Glutamine | 10 | 2013 | 175 | 2.090 |
Why?
| | Antibiotics, Antineoplastic | 5 | 2017 | 77 | 1.990 |
Why?
| | Mammary Neoplasms, Experimental | 6 | 2011 | 121 | 1.490 |
Why?
| | Transcriptome | 3 | 2024 | 313 | 1.340 |
Why?
| | Glutathione | 9 | 2013 | 299 | 1.080 |
Why?
| | Heart Diseases | 4 | 2012 | 214 | 0.950 |
Why?
| | Anthracyclines | 1 | 2024 | 29 | 0.920 |
Why?
| | Myocardium | 5 | 2024 | 445 | 0.910 |
Why?
| | Paraffin Embedding | 1 | 2024 | 51 | 0.900 |
Why?
| | Formaldehyde | 1 | 2024 | 49 | 0.900 |
Why?
| | Heart | 4 | 2016 | 341 | 0.890 |
Why?
| | Sequence Analysis, RNA | 1 | 2024 | 88 | 0.870 |
Why?
| | Neutrophils | 1 | 2024 | 145 | 0.850 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2023 | 195 | 0.750 |
Why?
| | Liver Neoplasms | 2 | 2023 | 326 | 0.690 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2011 | 73 | 0.670 |
Why?
| | Ventricular Function, Left | 2 | 2017 | 169 | 0.650 |
Why?
| | Cyclophosphamide | 2 | 2011 | 168 | 0.650 |
Why?
| | Rats | 13 | 2024 | 3292 | 0.640 |
Why?
| | Adenocarcinoma | 3 | 2011 | 397 | 0.610 |
Why?
| | MicroRNAs | 1 | 2022 | 344 | 0.590 |
Why?
| | Chemokines | 1 | 2017 | 75 | 0.570 |
Why?
| | Stroke Volume | 1 | 2017 | 141 | 0.540 |
Why?
| | Exercise | 1 | 2019 | 516 | 0.460 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1025 | 0.450 |
Why?
| | Female | 21 | 2024 | 27081 | 0.440 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1172 | 0.420 |
Why?
| | Rats, Sprague-Dawley | 7 | 2024 | 1585 | 0.370 |
Why?
| | Neoadjuvant Therapy | 3 | 2022 | 120 | 0.370 |
Why?
| | Animals | 13 | 2024 | 13124 | 0.350 |
Why?
| | Mastectomy, Segmental | 2 | 2013 | 93 | 0.340 |
Why?
| | Biological Transport | 1 | 2010 | 164 | 0.330 |
Why?
| | Tamoxifen | 1 | 2010 | 60 | 0.330 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2010 | 60 | 0.330 |
Why?
| | Middle Aged | 9 | 2024 | 12611 | 0.330 |
Why?
| | Rats, Inbred F344 | 4 | 2011 | 197 | 0.330 |
Why?
| | Receptors, Estrogen | 1 | 2010 | 132 | 0.320 |
Why?
| | Cell Proliferation | 2 | 2010 | 985 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 833 | 0.300 |
Why?
| | Catheter Ablation | 1 | 2010 | 120 | 0.300 |
Why?
| | Humans | 15 | 2024 | 50503 | 0.290 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 5 | 2008 | 50 | 0.260 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2024 | 88 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2006 | 50 | 0.250 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 30 | 0.230 |
Why?
| | Carcinogens | 4 | 2008 | 196 | 0.230 |
Why?
| | Cell Adhesion Molecules | 1 | 2024 | 86 | 0.230 |
Why?
| | Leukocytes, Mononuclear | 2 | 2016 | 118 | 0.230 |
Why?
| | Tissue Fixation | 1 | 2024 | 34 | 0.230 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2006 | 213 | 0.220 |
Why?
| | Signal Transduction | 3 | 2018 | 1624 | 0.220 |
Why?
| | Adult | 7 | 2024 | 13577 | 0.220 |
Why?
| | Hepatitis B virus | 1 | 2023 | 26 | 0.220 |
Why?
| | Antigens, CD | 1 | 2024 | 222 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2003 | 77 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 1 | 2003 | 145 | 0.210 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2003 | 140 | 0.210 |
Why?
| | Administration, Oral | 4 | 2013 | 434 | 0.200 |
Why?
| | Cerebellum | 1 | 2003 | 131 | 0.200 |
Why?
| | Hepatocytes | 1 | 2023 | 178 | 0.200 |
Why?
| | Dietary Proteins | 1 | 2004 | 252 | 0.190 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 109 | 0.190 |
Why?
| | Schizophrenia | 1 | 2003 | 258 | 0.190 |
Why?
| | Aged | 5 | 2024 | 9741 | 0.180 |
Why?
| | Thrombocytopenia | 2 | 2012 | 81 | 0.170 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 143 | 0.170 |
Why?
| | Yoga | 1 | 2019 | 15 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2018 | 5 | 0.160 |
Why?
| | Paracrine Communication | 1 | 2018 | 12 | 0.150 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 102 | 0.150 |
Why?
| | Exercise Therapy | 1 | 2019 | 96 | 0.150 |
Why?
| | Exosomes | 1 | 2018 | 48 | 0.150 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 465 | 0.150 |
Why?
| | Matrix Metalloproteinases | 1 | 2017 | 46 | 0.140 |
Why?
| | Emotions | 1 | 2019 | 168 | 0.140 |
Why?
| | Caspase 3 | 2 | 2010 | 93 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2009 | 1436 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 1372 | 0.140 |
Why?
| | Random Allocation | 2 | 2009 | 289 | 0.130 |
Why?
| | Apoptosis | 3 | 2010 | 1097 | 0.130 |
Why?
| | Mental Health | 1 | 2019 | 228 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2017 | 180 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 106 | 0.130 |
Why?
| | DNA Methylation | 1 | 2020 | 550 | 0.130 |
Why?
| | Prospective Studies | 2 | 2019 | 2378 | 0.120 |
Why?
| | Pilot Projects | 1 | 2017 | 698 | 0.120 |
Why?
| | Models, Biological | 1 | 2018 | 716 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 475 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 955 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1000 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2004 | 128 | 0.110 |
Why?
| | Oxidative Stress | 2 | 2010 | 772 | 0.100 |
Why?
| | Molecular Sequence Annotation | 1 | 2012 | 27 | 0.100 |
Why?
| | Lymphopenia | 1 | 2012 | 18 | 0.100 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2003 | 136 | 0.100 |
Why?
| | Quality of Life | 1 | 2019 | 851 | 0.100 |
Why?
| | Radiotherapy | 1 | 2013 | 125 | 0.100 |
Why?
| | Male | 4 | 2024 | 25907 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2013 | 112 | 0.090 |
Why?
| | Troponin I | 1 | 2011 | 18 | 0.090 |
Why?
| | Amino Acid Transport System ASC | 1 | 2010 | 4 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2010 | 17 | 0.090 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 457 | 0.080 |
Why?
| | Tumor Escape | 1 | 2010 | 17 | 0.080 |
Why?
| | DNA Fragmentation | 1 | 2010 | 53 | 0.080 |
Why?
| | Heart Function Tests | 1 | 2009 | 11 | 0.080 |
Why?
| | Troponin | 1 | 2009 | 12 | 0.080 |
Why?
| | Peroxynitrous Acid | 1 | 2009 | 33 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 101 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 36 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 150 | 0.080 |
Why?
| | von Willebrand Factor | 1 | 2009 | 42 | 0.080 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2010 | 82 | 0.080 |
Why?
| | Lipid Peroxidation | 1 | 2009 | 96 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2010 | 268 | 0.080 |
Why?
| | Killer Cells, Natural | 1 | 2010 | 106 | 0.080 |
Why?
| | Muscle Cells | 1 | 2009 | 22 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2012 | 1197 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 148 | 0.080 |
Why?
| | Eating | 1 | 2009 | 158 | 0.080 |
Why?
| | Estradiol | 1 | 2010 | 221 | 0.080 |
Why?
| | Body Weight | 1 | 2011 | 517 | 0.080 |
Why?
| | Glycine | 1 | 2009 | 78 | 0.080 |
Why?
| | Necrosis | 1 | 2009 | 174 | 0.080 |
Why?
| | Cell Survival | 1 | 2010 | 589 | 0.070 |
Why?
| | Antioxidants | 1 | 2010 | 239 | 0.070 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2008 | 35 | 0.070 |
Why?
| | Ultrasonography | 1 | 2009 | 435 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 400 | 0.070 |
Why?
| | Gene Expression | 1 | 2010 | 610 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2009 | 957 | 0.070 |
Why?
| | Young Adult | 1 | 2016 | 4102 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 1398 | 0.060 |
Why?
| | Adolescent | 1 | 2016 | 6443 | 0.060 |
Why?
| | bcl-2-Associated X Protein | 1 | 2004 | 57 | 0.060 |
Why?
| | Caspases | 1 | 2004 | 103 | 0.060 |
Why?
| | Models, Animal | 1 | 2004 | 227 | 0.060 |
Why?
| | Receptors, Somatomedin | 1 | 2003 | 8 | 0.060 |
Why?
| | Women's Health | 1 | 2003 | 85 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2003 | 156 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 192 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2003 | 277 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 136 | 0.050 |
Why?
| | Down-Regulation | 1 | 2003 | 340 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2003 | 552 | 0.050 |
Why?
| | Up-Regulation | 1 | 2003 | 446 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2004 | 449 | 0.040 |
Why?
| | CpG Islands | 1 | 2020 | 108 | 0.040 |
Why?
| | Diffusion Chambers, Culture | 1 | 2018 | 6 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 15 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2018 | 47 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2018 | 36 | 0.040 |
Why?
| | Laminin | 1 | 2018 | 18 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2018 | 55 | 0.040 |
Why?
| | Proteoglycans | 1 | 2018 | 83 | 0.040 |
Why?
| | Drug Combinations | 1 | 2018 | 127 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2018 | 142 | 0.040 |
Why?
| | Cell Death | 1 | 2018 | 175 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 320 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 198 | 0.040 |
Why?
| | Cell Movement | 1 | 2018 | 247 | 0.040 |
Why?
| | Collagen | 1 | 2018 | 204 | 0.030 |
Why?
| | Angiopoietin-2 | 1 | 2017 | 15 | 0.030 |
Why?
| | Angiopoietin-1 | 1 | 2017 | 16 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2017 | 16 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2017 | 34 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 45 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 97 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 222 | 0.030 |
Why?
| | Transcription Factors | 1 | 2020 | 565 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 182 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 382 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 155 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2003 | 3226 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 533 | 0.030 |
Why?
| | Intestinal Mucosa | 2 | 2008 | 216 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 62 | 0.030 |
Why?
| | Myoglobin | 1 | 2013 | 25 | 0.030 |
Why?
| | Blood Proteins | 1 | 2013 | 84 | 0.030 |
Why?
| | Diet | 2 | 2008 | 568 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 708 | 0.020 |
Why?
| | Pyroglutamate Hydrolase | 1 | 2008 | 2 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2008 | 4 | 0.020 |
Why?
| | Glutamate-Cysteine Ligase | 1 | 2008 | 21 | 0.020 |
Why?
| | Glutaminase | 1 | 2008 | 18 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 2242 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 5283 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2008 | 1089 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 60 | 0.010 |
Why?
| | Arteries | 1 | 2003 | 91 | 0.010 |
Why?
| | Breast | 1 | 2003 | 85 | 0.010 |
Why?
|
|
Todorova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|